NBN and prostate carcinoma: A combined therapy with olaparib and double immunotherapy (durvalumab and tremelimumab) showed its efficacy in patients with alterations in HR repair genes (including NBN, RAD50 and MRE11) in breast, ovarian, pancreatic, endometrial, or prostate cancers [137].